Oncogene mutational profile in nasopharyngeal carcinoma. - Wikidata - wikimedia - TriplyDB

Oncogene mutational profile in nasopharyngeal carcinoma.

Oncogene mutational profile in nasopharyngeal carcinoma.

http://www.wikidata.org/entity/Q37660226

about

Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma.Genetic variations in the PI3K/PTEN/AKT/mTOR pathway predict tumor response and disease-free survival in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy and radical surgery.Prognostic analysis of patients with locally advanced nasopharyngeal carcinoma following intensity modulated radiation therapy.

P2860

Q36121338-4100349B-A83D-4AAF-96E7-5000DC5A2017 Q36220797-7285A6E2-7931-4BAC-81D7-D5FCD21D5E90 Q36278144-97A8DA09-0783-494F-A88C-3B468D153630 Q37269328-E515B07F-71E0-4C42-BBCD-DD08FC3B8252 Q37317549-010C4358-73A8-472B-81A0-B811CD21B538 Q37678950-704AEB72-AB13-417B-AEE4-F757414B4C81 Q38845519-24EE91E9-ED7B-431A-A2E5-71ED91AB2334 Q47138360-8F41AB08-DA24-4B92-90A3-1D8885F0983B Q52629228-990420C9-B590-4987-B5DE-E8E416BA2647 Q55065500-2668B0BC-C79B-4923-B98A-4791F017BD78

P2860

Oncogene mutational profile in nasopharyngeal carcinoma.

http://www.wikidata.org/entity/Q37660226

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Oncogene mutational profile in nasopharyngeal carcinoma.

@en

Oncogene mutational profile in nasopharyngeal carcinoma.

@nl

type

label

Oncogene mutational profile in nasopharyngeal carcinoma.

@en

Oncogene mutational profile in nasopharyngeal carcinoma.

@nl

prefLabel

Oncogene mutational profile in nasopharyngeal carcinoma.

@en

Oncogene mutational profile in nasopharyngeal carcinoma.

@nl

P1433

Q37660226-BBE89552-ACD5-4EF4-B8D1-F1938249FB51

P1476

Q37660226-1410CE5C-EDA5-494D-A78F-3B3D06BD17CE

P2093

Q37660226-384F9817-C83C-45D8-94DB-EF6C92EE71B5

Q37660226-4BA32D74-DCD3-459B-BC91-A1E16772ED2C

Q37660226-87426E36-2FE4-4A5C-AB20-5D54BE97CB56

Q37660226-9A86A278-7618-474F-82EB-E023FC114802

Q37660226-BD6987B7-C0D6-42A1-9885-46F727762AEE

Q37660226-F7984AB6-125B-41D3-9D61-5B791832EEA4

P2860

Q37660226-0040F757-8CA8-4BF9-9DF5-3D3394DAFDEE

Q37660226-03B6F61F-82BB-4F0F-A127-0C678987947D

Q37660226-060EA60E-9EB9-4E56-A5CD-98105AAB91B4

Q37660226-0D9C94A0-D2B7-45EA-8AE3-65B2F8CB6545

Q37660226-16EE5A55-1DB8-4AE8-9814-D84B09777BDC

Q37660226-19AF1729-03D7-4289-AA23-592F9AE3707D

Q37660226-1D2EBE0E-8266-42BC-84A5-57E3F7D56150

Q37660226-1DF99E7D-74EC-4C72-B266-A628EF81D05B

Q37660226-2E1E663B-6B9D-4CD3-BA8F-738D8833A819

Q37660226-33EC339D-3284-47F2-81BE-7CC010CCA7FA

P304

Q37660226-D442E4DC-2E94-43DF-A2DB-CA49BBDBDDB7

P31

Q37660226-2CCB0902-763F-404B-A685-671C84076045

P356

Q37660226-FFEADB9A-6E56-4AA6-AEF5-FE59B6A73460

P407

Q37660226-6143610B-5EFD-40EB-9E20-E08E44EAC1DF

P478

Q37660226-055E7D33-4610-4D13-91B5-67E66329D2B0

P577

Q37660226-7DEABF6C-46FB-4346-BD9D-7892A9902A17

P698

Q37660226-725C4D31-E776-4F4F-8113-B3B3CC099131

P932

Q37660226-44EDCB84-0175-4133-A763-7E9806E02BA5

P356

P1433

OncoTargets and Therapy

P1476

Oncogene mutational profile in nasopharyngeal carcinoma.

@en

P2093

Fang Wang

http://www.w3.org/2001/XMLSchema#string

Hai-Yun Wang

http://www.w3.org/2001/XMLSchema#string

Jian-Yong Shao

http://www.w3.org/2001/XMLSchema#string

Sha Fu

http://www.w3.org/2001/XMLSchema#string

Yi-Xin Zeng

http://www.w3.org/2001/XMLSchema#string

Zi-Chen Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci

Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials.

Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China.

The PIK3CA gene as a mutated target for cancer therapy.

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001

P304

457-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S58791

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24672248

http://www.w3.org/2001/XMLSchema#string

P932

3964172

http://www.w3.org/2001/XMLSchema#string